1999
DOI: 10.1016/s0014-2999(99)00674-3
|View full text |Cite
|
Sign up to set email alerts
|

Modulation of actomyosin ATPase by thiotetromycin is mediated through conformational change of actin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2000
2000
2008
2008

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 24 publications
0
3
0
Order By: Relevance
“…The antibiotic has inhibitory activity against type II fatty acid synthase (FAS) 38) . Recently, it was found that thiotetromycin induces modulation of actomyosin ATPase activity mediated through a conformational change in action 39) . An analogue of this compound, thiolactomycin, is the focus of attention as it is reported to exhibit anti-malarial activity by inhibiting type II fatty acid biosynthesis in apicoplasts 40) and antimycoplasmal activity by specifically inhibiting fatty acid and mycolic acid biosynthesis 41), 42) .…”
Section: -3 Screeningmentioning
confidence: 99%
“…The antibiotic has inhibitory activity against type II fatty acid synthase (FAS) 38) . Recently, it was found that thiotetromycin induces modulation of actomyosin ATPase activity mediated through a conformational change in action 39) . An analogue of this compound, thiolactomycin, is the focus of attention as it is reported to exhibit anti-malarial activity by inhibiting type II fatty acid biosynthesis in apicoplasts 40) and antimycoplasmal activity by specifically inhibiting fatty acid and mycolic acid biosynthesis 41), 42) .…”
Section: -3 Screeningmentioning
confidence: 99%
“…Ninety-percent of the 1999 publications reported using BIACORE technology (Biacore AB, Uppsala, Sweden); 1-457 8% reported using IAsys (Affinity Sensors, Franklin, MA); and 2% reported using other instruments, including IBIS (Windsor Scientific Limited, Berks, UK), 507 SPR-670 (Nippon Laser and Electronics Laboratory, Hokkaido, Japan), 499,500,504,506 TISPR-1 (Texas Instruments, Dallas, TX), 497,501 and an instrument produced by Johnson & Johnson Orthoclinical Diagnostics Ltd (Chalfont St Giles, UK). The popularity of the technology continues to grow, as evidenced by the yearly increase in the number of scientific publications describing experiments using SPR.…”
Section: Introductionmentioning
confidence: 99%
“…There are several manufacturers of biosensor platforms. Ninety-percent of the 1999 publications reported using BIACORE technology (Biacore AB, Uppsala, Sweden); 1-457 8% reported using IAsys (Affinity Sensors, Franklin, MA); and 2% reported using other instruments, including IBIS (Windsor Scientific Limited, Berks, UK), 507 SPR-670 (Nippon Laser and Electronics Laboratory, Hokkaido, Japan), 499,500,504,506 TISPR-1 (Texas Instruments, Dallas, TX), 497,501 and an instrument produced by Johnson & Johnson Orthoclinical Diagnostics Ltd (Chalfont St Giles, UK). 498,502,503,505 Given the large number of publications describing the use of BIACORE technology, these references are subdivided into the following categories: reviews, 1-10 methods, 11-16 mass transport, 17-22 antibodies, 23-102 proteins, 103-203 cell surface receptors, extracellular matrix, peptides, oligonucleotides, carbohydrates, [389][390][391][392][393][394] small molecules, lipids, 416-442 cells and particles, [443][444][445][446][447][448] complex analytes [449][450][451][452][453][454] and other systems.…”
Section: Introductionmentioning
confidence: 99%